Detail akcie Repare Therap Rg online

Business Summary: Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Repare Therapeutics Inc revenues decreased 100% to $250K. Net loss increased from $21.6M to $46.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Interest income decrease of 53% to $2.8M (income). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.51 to -$1.10.